PL3456333T3 - Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego - Google Patents

Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego

Info

Publication number: PL3456333T3
Authority: PL; Poland
Prior art keywords: imetelstat; treatment; telomerase inhibitor; myelodisplastic syndrome; myelodisplastic
Prior art date: 2012-12-07

Application number

PL18196690T

Other languages

English (en)

Inventor

Monic J. Stuart

Stephen Kelsey

Original Assignee

Geron Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-07

Filing date

2013-11-15

Publication date

2020-09-21

2013-03-15 Priority claimed from US13/841,711 external-priority patent/US9375485B2/en

2013-11-15 Application filed by Geron Corporation filed Critical Geron Corporation

2020-09-21 Publication of PL3456333T3 publication Critical patent/PL3456333T3/pl

Links

229940123582 Telomerase inhibitor Drugs 0.000 title 1
LVZYXEALRXBLJZ-ISQYCPACSA-N f60ne4xb53 Chemical compound N1([C@@H]2O[C@@H]([C@H](C2)NP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP(S)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O LVZYXEALRXBLJZ-ISQYCPACSA-N 0.000 title 1
229950004291 imetelstat Drugs 0.000 title 1
208000011580 syndromic disease Diseases 0.000 title 1
239000003277 telomerase inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Oncology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Compounds Of Unknown Constitution (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL18196690T 2012-12-07 2013-11-15 Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego PL3456333T3 (pl)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201261734941P	2012-12-07	2012-12-07
US201361799069P	2013-03-15	2013-03-15
US13/841,711 US9375485B2 (en)	2012-12-07	2013-03-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P	2013-11-05	2013-11-05
PCT/US2013/070437 WO2014088785A1 (en)	2012-12-07	2013-11-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP18196690.4A EP3456333B8 (en)	2012-12-07	2013-11-15	Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome
EP13861008.4A EP2928477B1 (en)	2012-12-07	2013-11-15	Use of the telomerase inhibitor imetelstat for the treatment of myelofibrosis

Publications (1)

Publication Number	Publication Date
PL3456333T3 true PL3456333T3 (pl)	2020-09-21

Family

ID=50883867

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL19187756.2T PL3646876T3 (pl)	2012-12-07	2013-11-15	Inhibitor telomerazy, imetelstat do leczenia zaburzeń mieloproliferacyjnych i nowotworów mieloproliferacyjnych
PL18196690T PL3456333T3 (pl)	2012-12-07	2013-11-15	Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego
PL13861008T PL2928477T3 (pl)	2012-12-07	2013-11-15	Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL19187756.2T PL3646876T3 (pl)	2012-12-07	2013-11-15	Inhibitor telomerazy, imetelstat do leczenia zaburzeń mieloproliferacyjnych i nowotworów mieloproliferacyjnych

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL13861008T PL2928477T3 (pl)	2012-12-07	2013-11-15	Zastosowanie inhibitora telomerazy imetelstatu do leczenia mielofibrozy

Country Status (35)

Country	Link
EP (3)	EP3646876B1 (pl)
JP (5)	JP6433911B2 (pl)
KR (3)	KR102294819B1 (pl)
CN (2)	CN104936602B (pl)
AP (1)	AP2015008504A0 (pl)
AU (4)	AU2013356533B2 (pl)
BR (1)	BR112015013260A2 (pl)
CA (2)	CA2892907C (pl)
CL (2)	CL2015001530A1 (pl)
CY (2)	CY1122169T1 (pl)
DK (3)	DK3456333T3 (pl)
EA (1)	EA032973B1 (pl)
ES (3)	ES2744790T3 (pl)
FI (1)	FI3646876T3 (pl)
HK (2)	HK1210940A1 (pl)
HR (3)	HRP20240624T1 (pl)
HU (3)	HUE066402T2 (pl)
IL (3)	IL317233A (pl)
LT (3)	LT3646876T (pl)
MA (2)	MA38193B1 (pl)
ME (1)	ME03538B (pl)
MX (3)	MX2015007169A (pl)
MY (1)	MY180634A (pl)
NZ (1)	NZ708920A (pl)
PH (2)	PH12019501008A1 (pl)
PL (3)	PL3646876T3 (pl)
PT (3)	PT3646876T (pl)
RS (2)	RS60401B1 (pl)
SG (3)	SG11201504383TA (pl)
SI (3)	SI3456333T1 (pl)
SM (2)	SMT201900567T1 (pl)
TN (1)	TN2015000249A1 (pl)
UA (3)	UA117116C2 (pl)
WO (1)	WO2014088785A1 (pl)
ZA (2)	ZA201504124B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2643296T3 (es)	2004-07-02	2017-11-22	Geron Corporation	Síntesis de monómeros nucleosídicos 3'-aminoprotegidos
SG10201801069QA (en)	2013-08-07	2018-03-28	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
JP6532478B2 (ja)	2013-11-06	2019-06-19	メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ	血液悪性腫瘍を処置するための方法および材料
MD3286203T2 (ro) *	2015-04-23	2020-08-31	Geron Corp	Metode de preparare a polinucleotidelor folosind compoziții de săruri de cationi multivalenți
EP3318276A1 (en)	2016-11-04	2018-05-09	Janssen Biotech, Inc.	Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
UA127701C2 (uk) *	2017-07-28	2023-12-06	Джерон Корпорейшн	Спосіб лікування мієлодиспластичного синдрому (варіанти)
CR20200576A (es) *	2018-04-30	2021-04-30	Kartos Therapeutics Inc	Métodos para tratar cáncer
AU2019315406B2 (en) *	2018-07-31	2025-02-27	Geron Corporation	Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor
JP2022513162A (ja)	2018-11-29	2022-02-07	ジェロン・コーポレーション	骨髄異形成症候群を治療する方法
WO2021091904A1 (en) *	2019-11-04	2021-05-14	Geron Corporation	Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms
JP2021157248A (ja) *	2020-03-25	2021-10-07	パイオニア株式会社	状況出力装置
WO2024259369A1 (en) *	2023-06-14	2024-12-19	Rarecells Inc.	Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5489508A (en)	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en)	1994-07-07	1996-12-10	Geron Corporation	Mammalian telomerase
US5958680A (en)	1994-07-07	1999-09-28	Geron Corporation	Mammalian telomerase
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US5770613A (en)	1995-09-29	1998-06-23	Geron Corporation	Telomerase inhibitors
US5767278A (en)	1995-10-06	1998-06-16	Geron Corporation	Telomerase inhibitors
US6261836B1 (en)	1996-10-01	2001-07-17	Geron Corporation	Telomerase
US6444650B1 (en)	1996-10-01	2002-09-03	Geron Corporation	Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
AU733610B2 (en)	1996-12-20	2001-05-17	Geron Corporation	Methods for detecting and inhibiting the RNA component of telomerase
US6331399B1 (en)	2000-05-16	2001-12-18	Isis Pharmaceuticals, Inc.	Antisense inhibition of tert expression
WO2004070008A2 (en) *	2003-01-31	2004-08-19	Au Jessie L-S	Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) *	2003-07-11	2006-03-08	暨南大学	抑制白血病细胞端粒酶活性的反义核酸及其应用
CN100393209C (zh)	2003-09-09	2008-06-11	杰龙公司	用于端粒酶抑制的改性寡核苷酸
US20050282893A1 (en) *	2004-01-30	2005-12-22	Au Jessie L	Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
ES2643296T3 (es)	2004-07-02	2017-11-22	Geron Corporation	Síntesis de monómeros nucleosídicos 3'-aminoprotegidos
FR2877013A1 (fr)	2004-10-27	2006-04-28	Assist Publ Hopitaux De Paris	Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en)	2005-01-21	2006-07-27	Bahou Wadie F	Methods of diagnosing essential thrombocythemia
ATE553198T1 (de)	2005-04-15	2012-04-15	Geron Corp	Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten
WO2006113426A2 (en) *	2005-04-15	2006-10-26	Geron Corporation	Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en)	2006-03-15	2007-09-27	The Methodist Hospital Research Institute	System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en)	2006-07-21	2008-01-24	Cephalon, Inc.	JAK inhibitors for treatment of myeloproliferative disorders
EP4474480A2 (en) *	2006-10-30	2024-12-11	Geron Corporation	Combined telomerase inhibitor and gemcitabine for the treatment of cancer
CN101220044B (zh) *	2008-01-21	2010-06-02	中国药科大学	端粒酶抑制剂及其制备方法和用途

2013
- 2013-11-15 DK DK18196690.4T patent/DK3456333T3/da active
- 2013-11-15 MY MYPI2015001459A patent/MY180634A/en unknown
- 2013-11-15 SI SI201331716T patent/SI3456333T1/sl unknown
- 2013-11-15 HR HRP20240624TT patent/HRP20240624T1/hr unknown
- 2013-11-15 PL PL19187756.2T patent/PL3646876T3/pl unknown
- 2013-11-15 ES ES13861008T patent/ES2744790T3/es active Active
- 2013-11-15 ME MEP-2019-273A patent/ME03538B/me unknown
- 2013-11-15 CA CA2892907A patent/CA2892907C/en active Active
- 2013-11-15 LT LTEP19187756.2T patent/LT3646876T/lt unknown
- 2013-11-15 EP EP19187756.2A patent/EP3646876B1/en active Active
- 2013-11-15 LT LTEP18196690.4T patent/LT3456333T/lt unknown
- 2013-11-15 MA MA38193A patent/MA38193B1/fr unknown
- 2013-11-15 ES ES18196690T patent/ES2789176T3/es active Active
- 2013-11-15 WO PCT/US2013/070437 patent/WO2014088785A1/en active Application Filing
- 2013-11-15 PT PT191877562T patent/PT3646876T/pt unknown
- 2013-11-15 LT LTEP13861008.4T patent/LT2928477T/lt unknown
- 2013-11-15 PL PL18196690T patent/PL3456333T3/pl unknown
- 2013-11-15 RS RS20200723A patent/RS60401B1/sr unknown
- 2013-11-15 HU HUE19187756A patent/HUE066402T2/hu unknown
- 2013-11-15 SM SM20190567T patent/SMT201900567T1/it unknown
- 2013-11-15 CN CN201380069553.6A patent/CN104936602B/zh active Active
- 2013-11-15 PL PL13861008T patent/PL2928477T3/pl unknown
- 2013-11-15 AU AU2013356533A patent/AU2013356533B2/en active Active
- 2013-11-15 FI FIEP19187756.2T patent/FI3646876T3/fi active
- 2013-11-15 JP JP2015546492A patent/JP6433911B2/ja active Active
- 2013-11-15 UA UAA201505480A patent/UA117116C2/uk unknown
- 2013-11-15 UA UAA202100419A patent/UA128370C2/uk unknown
- 2013-11-15 CA CA3188494A patent/CA3188494A1/en active Pending
- 2013-11-15 BR BR112015013260-0A patent/BR112015013260A2/pt not_active Application Discontinuation
- 2013-11-15 HU HUE18196690A patent/HUE049858T2/hu unknown
- 2013-11-15 SG SG11201504383TA patent/SG11201504383TA/en unknown
- 2013-11-15 EP EP13861008.4A patent/EP2928477B1/en active Active
- 2013-11-15 KR KR1020157017240A patent/KR102294819B1/ko active IP Right Grant
- 2013-11-15 SI SI201332080T patent/SI3646876T1/sl unknown
- 2013-11-15 SI SI201331556T patent/SI2928477T1/sl unknown
- 2013-11-15 ES ES19187756T patent/ES2982897T3/es active Active
- 2013-11-15 SM SM20200328T patent/SMT202000328T1/it unknown
- 2013-11-15 EP EP18196690.4A patent/EP3456333B8/en active Active
- 2013-11-15 AP AP2015008504A patent/AP2015008504A0/xx unknown
- 2013-11-15 SG SG10201802926XA patent/SG10201802926XA/en unknown
- 2013-11-15 UA UAA201800703A patent/UA126015C2/uk unknown
- 2013-11-15 SG SG10202103341SA patent/SG10202103341SA/en unknown
- 2013-11-15 DK DK13861008.4T patent/DK2928477T3/da active
- 2013-11-15 PH PH1/2019/501008A patent/PH12019501008A1/en unknown
- 2013-11-15 PT PT181966904T patent/PT3456333T/pt unknown
- 2013-11-15 HU HUE13861008A patent/HUE045098T2/hu unknown
- 2013-11-15 CN CN202010575187.3A patent/CN111617252A/zh active Pending
- 2013-11-15 KR KR1020237005641A patent/KR20230028590A/ko not_active Application Discontinuation
- 2013-11-15 NZ NZ708920A patent/NZ708920A/en unknown
- 2013-11-15 MX MX2015007169A patent/MX2015007169A/es active IP Right Grant
- 2013-11-15 EA EA201590878A patent/EA032973B1/ru unknown
- 2013-11-15 PT PT138610084T patent/PT2928477T/pt unknown
- 2013-11-15 IL IL317233A patent/IL317233A/en unknown
- 2013-11-15 IL IL280144A patent/IL280144B1/en unknown
- 2013-11-15 RS RSP20191271 patent/RS59363B1/sr unknown
- 2013-11-15 KR KR1020217026717A patent/KR102662590B1/ko active IP Right Grant
- 2013-11-15 MA MA45504A patent/MA45504B1/fr unknown
- 2013-11-15 DK DK19187756.2T patent/DK3646876T3/da active
2015
- 2015-06-04 CL CL2015001530A patent/CL2015001530A1/es unknown
- 2015-06-05 MX MX2020003276A patent/MX2020003276A/es unknown
- 2015-06-05 TN TNP2015000249A patent/TN2015000249A1/fr unknown
- 2015-06-05 PH PH12015501282A patent/PH12015501282A1/en unknown
- 2015-06-05 MX MX2022015437A patent/MX2022015437A/es unknown
- 2015-06-07 IL IL23926615A patent/IL239266B/en active IP Right Grant
- 2015-06-08 ZA ZA2015/04124A patent/ZA201504124B/en unknown
- 2015-11-27 HK HK15111700.1A patent/HK1210940A1/xx unknown
2016
- 2016-01-08 HK HK16100186.6A patent/HK1212226A1/xx unknown
2017
- 2017-08-24 CL CL2017002156A patent/CL2017002156A1/es unknown
- 2017-12-04 JP JP2017232485A patent/JP6998191B2/ja active Active
2018
- 2018-12-20 AU AU2018282364A patent/AU2018282364A1/en not_active Abandoned
2019
- 2019-10-02 HR HRP20191784TT patent/HRP20191784T1/hr unknown
- 2019-10-14 CY CY20191101076T patent/CY1122169T1/el unknown
- 2019-12-23 JP JP2019231517A patent/JP2020041001A/ja active Pending
2020
- 2020-06-23 CY CY20201100568T patent/CY1123206T1/el unknown
- 2020-06-24 HR HRP20200993TT patent/HRP20200993T1/hr unknown
- 2020-11-09 AU AU2020267142A patent/AU2020267142C1/en active Active
2021
- 2021-11-12 ZA ZA2021/08991A patent/ZA202108991B/en unknown
2022
- 2022-01-06 JP JP2022000951A patent/JP7288098B2/ja active Active
- 2022-10-12 JP JP2022163881A patent/JP2022179684A/ja active Pending
2024
- 2024-05-13 AU AU2024203138A patent/AU2024203138A1/en active Pending

Also Published As

Publication number	Publication date
IL280144A (en)	2021-03-01
HRP20240624T1 (hr)	2024-08-02
AU2013356533B2 (en)	2018-09-27
LT3646876T (lt)	2024-05-10
DK3456333T3 (da)	2020-05-18
CN111617252A (zh)	2020-09-04
ES2982897T3 (es)	2024-10-18
MX2020003276A (es)	2020-07-20
CY1122169T1 (el)	2020-11-25
SMT201900567T1 (it)	2019-11-13
CN104936602B (zh)	2020-07-17
MX2022015437A (es)	2023-01-11
LT3456333T (lt)	2020-06-25
KR20210107906A (ko)	2021-09-01
UA128370C2 (uk)	2024-06-26
AU2020267142C1 (en)	2024-08-08
UA126015C2 (uk)	2022-08-03
IL239266B (en)	2019-11-28
PH12019501008A1 (en)	2022-11-14
SI2928477T1 (sl)	2019-11-29
ME03538B (me)	2020-07-20
HUE049858T2 (hu)	2020-11-30
NZ708920A (en)	2020-08-28
EP3456333B1 (en)	2020-04-01
SG10201802926XA (en)	2018-05-30
CA2892907A1 (en)	2014-06-12
HK1212226A1 (en)	2016-06-10
JP6998191B2 (ja)	2022-02-04
ES2744790T3 (es)	2020-02-26
UA117116C2 (uk)	2018-06-25
KR102662590B1 (ko)	2024-05-03
EA201590878A1 (ru)	2016-04-29
PT3646876T (pt)	2024-05-15
ES2789176T3 (es)	2020-10-26
CN104936602A (zh)	2015-09-23
HRP20200993T1 (hr)	2020-11-27
HUE045098T2 (hu)	2019-12-30
AU2020267142B2 (en)	2024-05-16
SI3646876T1 (sl)	2024-07-31
AU2018282364A1 (en)	2019-05-23
RS60401B1 (sr)	2020-07-31
CY1123206T1 (el)	2021-10-29
HRP20191784T1 (hr)	2019-12-27
AU2013356533A1 (en)	2014-06-12
IL317233A (en)	2025-01-01
EP2928477A4 (en)	2016-09-21
ZA202108991B (en)	2023-05-31
JP2018035196A (ja)	2018-03-08
SI3456333T1 (sl)	2020-10-30
HK1210940A1 (en)	2016-05-13
DK3646876T3 (da)	2024-05-06
MA45504B1 (fr)	2021-10-29
SG11201504383TA (en)	2015-07-30
NZ748134A (en)	2020-10-30
EP3456333B8 (en)	2020-05-13
EP2928477B1 (en)	2019-07-24
PH12015501282B1 (en)	2015-08-24
JP2020041001A (ja)	2020-03-19
WO2014088785A8 (en)	2015-07-16
PT2928477T (pt)	2019-10-25
PL2928477T3 (pl)	2020-03-31
RS59363B1 (sr)	2019-11-29
MA38193B1 (fr)	2018-12-31
EP3456333A1 (en)	2019-03-20
SG10202103341SA (en)	2021-05-28
DK2928477T3 (da)	2019-10-07
EP3646876A1 (en)	2020-05-06
JP7288098B2 (ja)	2023-06-06
HUE066402T2 (hu)	2024-07-28
EA032973B1 (ru)	2019-08-30
TN2015000249A1 (en)	2016-10-03
ZA201504124B (en)	2017-05-31
AP2015008504A0 (en)	2015-06-30
KR20150091130A (ko)	2015-08-07
JP2022050537A (ja)	2022-03-30
EP2928477A1 (en)	2015-10-14
MA45504A1 (fr)	2020-05-29
PH12015501282A1 (en)	2015-08-24
MA38193A1 (fr)	2017-12-29
KR102294819B1 (ko)	2021-09-01
AU2020267142A1 (en)	2020-12-03
AU2024203138A1 (en)	2024-07-25
PT3456333T (pt)	2020-06-01
LT2928477T (lt)	2019-10-10
EP3646876B1 (en)	2024-02-14
CL2017002156A1 (es)	2018-05-04
WO2014088785A1 (en)	2014-06-12
IL280144B1 (en)	2025-01-01
JP2022179684A (ja)	2022-12-02
MX2015007169A (es)	2016-03-31
IL239266A0 (en)	2015-07-30
KR20230028590A (ko)	2023-02-28
JP6433911B2 (ja)	2018-12-05
MY180634A (en)	2020-12-03
JP2016504307A (ja)	2016-02-12
PL3646876T3 (pl)	2024-07-22
BR112015013260A2 (pt)	2018-02-06
CA2892907C (en)	2023-03-21
CA3188494A1 (en)	2014-06-12
FI3646876T3 (fi)	2024-05-14
SMT202000328T1 (it)	2020-07-08
CL2015001530A1 (es)	2016-03-28

Publication	Publication Date	Title
IL285843A (en)	2021-09-30	Ibrutinib for use in the treatment of chronic graft versus host disease
HRP20181679T1 (hr)	2018-12-14	Amidni spojevi za liječenje hiv
PL3456333T3 (pl)	2020-09-21	Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego
IL243976B (en)	2020-07-30	kdm1a inhibitors for disease treatment
SMT201700003B (it)	2017-03-08	Didropiridoni come inibitori del fattore xia
DK2919796T3 (da)	2021-05-31	Brug af akkermansia til behandling af stofskiftesygdomme
LT2984166T (lt)	2020-08-10	Kompozicijos, skirtos mpsi gydymui
HK1211210A1 (zh)	2016-05-20	治療多發性硬化症的組合療法
LT2885010T (lt)	2020-04-27	Tautopatijos gydymo būdai
HUE042763T2 (hu)	2019-07-29	Módosított szerpinek vérzési rendellenességek kezelésére
LT3495495T (lt)	2021-02-25	Diagnostiniai žymenys ląstelių proliferacijos sutrikimų gydymui telomerazės inhibitoriais
LT2812013T (lt)	2019-07-10	Kompozicija, skirta džs gydymui
ZA202207530B (en)	2023-10-25	Use of phenoxypropylamine compounds to treat depression
DK2976101T3 (da)	2020-11-23	Behandlingsfremgangsmåde
DK2988750T3 (da)	2022-04-04	Anvendelse af landiololhydrochlorid til langtidsbehandling af takyarytmier
ITRM20120473A1 (it)	2014-04-05	Use of glycerophosphoinositols for the treatment of septic shock
DK3041506T3 (da)	2023-02-27	Behandlingsfremgangsmåde
TH1501001181A (th)	2016-08-03	องค์ประกอบสำหรับรักษาโรคสะเก็ดเงิน
TH1401007179A (th)	2016-07-06	องค์ประกอบและการใช้ของมันเพื่อป้องกันและรักษาตับอักเสบบี